Oncotarget

Clinical Research Papers:

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin

Wei Cui _, Wenzhe Fan, Qun Zhang, Jia Wen, Yonghui Huang, Jianyong Yang, Jiaping Li and Yu Wang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:79165-79174. https://doi.org/10.18632/oncotarget.16298

Metrics: PDF 1028 views  |   HTML 1686 views  |   ?  


Abstract

Wei Cui1, Wenzhe Fan1, Qun Zhang2, Jia Wen1,Yonghui Huang3, Jianyong Yang3, Jiaping Li1 and Yu Wang1

1 Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

2 Department of Radiotherapy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

3 Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Correspondence to:

Jiaping Li, email:

Yu Wang, email:

Keywords: liver neoplasm; transarterial chemoembolization (TACE); raltitrexed; fluorouracil; chemotherapy

Received: December 02, 2016 Accepted: March 01, 2017 Published: March 16, 2017

Abstract

Aims: To compare the safety and efficacy of TACE using raltitrexed, oxaliplatin and epirubicin with 5-fluorouracil, oxaliplatin and epirubicin for patients with unresectable hepatocelluar carcinoma.

Results: Median overall survival (OS) was 7.4 months in the raltitrexed group [95% confidence interval (CI): 5.4, 9.4) and 5.8 months in the control group (95% CI: 5.2, 6.4; P = 0.177). The median progression-free survival (PFS) time was significantly higher in the raltitrexed group (3.6 months, 95% CI: 2.8, 4.4) than in the control group (2.6 months, 95% CI: 2.2, 3.0; P = 0.038). The disease control rate (DCR) was higher in the raltitrexed group than in the control group (40% versus 30.4%; P = 0.353). The incidence of adverse events was similar between the two groups.

Materials and Methods: From January 2012 to December 2014, 86 patients with unresectable HCC were treated with TACE using the combination of raltitrexed, oxaliplatin and epirubicin (raltitrexed group), and the combination of 5-fluorouracil, oxaliplatin and epirubicin (control group). The primary endpoint was OS, and the secondary endpoints were PFS, DCR and adverse events.

Conclusions: Although the study did not meet its primary endpoint, raltitrexed group reach a higher PFS, which suggests that this combination regimen of TACE as alternative may confer some benefits to selected patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16298